Key result
LMWH provides more predictable anticoagulation than UFH during pregnancy without requiring routine monitoring.
Why the study?
Therapies aimed at preventing preeclampsia are essential due to its considerable morbidity and mortality, and understanding the pharmacokinetics and pharmacodynamics of LMWH in pregnancy is necessary for safe anticoagulant treatment.
Does low-molecular-weight heparin (LMWH) prevent preeclampsia and thrombotic injury in high-risk pregnant women?
Does low-molecular-weight heparin (LMWH) prevent preeclampsia and thrombotic injury in high-risk pregnant women?
LMWH offers a more predictable response than unfractionated heparin for preventing thrombotic injury in high-risk pregnant women, without the need for routine biological monitoring.
Answers are grounded in this paper and cite their sources.
LMWH preferred for anticoagulation in pregnancy due to placental safety; leaves open its preventive efficacy for preeclampsia in high-risk women without thrombophilia.
Preeclampsia is a disease characteristic only to human pregnancy, birth being its only healing method. The morbidity and mortality associated with this condition are considerable, therefore therapies aimed at preventing the development of preeclampsia, which could delay the onset of the disease or decrease its severity, are essential. Pregnant women with an increased risk of thromboembolic disease require anticoagulant treatment throughout pregnancy. The effects and pharmacokinetics of the anticoagulant treatment used are mandatory to be known, given that in some cases the teratogenic effect may be present and in all cases the adaptation of the treatment near and during labor must be individualized. The low-molecular-weight heparin (LMWH) response is more predictable than unfractionated heparin, and in the context of adverse effects and unlikely overdose, routine monitoring by biological tests is not required. For each patient undergoing anticoagulant treatment during pregnancy for the purpose of preventing thrombotic injury, there should be explained the signs and symptoms of thrombosis, taking into account the fact that, even though the thrombotic risk is very low under anticoagulant treatment, a degree of risk still persists in pregnancy. Preeclampsia risk assessment project aims to gather all the data regarding the personal and familial history, obsterical and clinical data that impact the risk of developing a hypertensive pathology in pregnancy.
No takes yet. Share an insight, caveat, or question.
Ţurcan et al. (2020) conducted a review in Preeclampsia and thromboembolic disease in pregnancy. Low-molecular-weight heparin (LMWH) vs. Unfractionated heparin was evaluated. Low-molecular-weight heparin provides a more predictable anticoagulant response than unfractionated heparin during pregnancy and does not require routine biological monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: